EGFR-IN-5, with the CAS number 2225887-26-1, is a chemical compound that functions as an inhibitor of the epidermal growth factor receptor (EGFR), which is a critical target in cancer therapy. This compound is designed to interfere with the signaling pathways that promote cell proliferation and survival in tumors expressing EGFR. Typically, EGFR inhibitors are characterized by their ability to bind to the receptor's active site or allosteric sites, thereby blocking its activation by natural ligands. The structure of EGFR-IN-5 likely includes specific functional groups that enhance its binding affinity and selectivity for the EGFR, contributing to its potential efficacy in treating various cancers, particularly those with EGFR mutations or overexpression. Additionally, the pharmacokinetic properties, such as solubility, stability, and bioavailability, are essential for its therapeutic application. As with many targeted therapies, understanding the compound's mechanism of action, potential side effects, and resistance mechanisms is crucial for its clinical use.

EGFR-IN-5

2225887-26-1: EGFR-IN-5, with the CAS number 2225887-26-1, is a chemical compound that functions as an inhibitor of the epidermal growth factor receptor (EGFR), which is a critical target in cancer therapy. This compound is designed to interfere with the signaling pathways that promote cell proliferation and survival in tumors expressing EGFR. Typically, EGFR inhibitors are characterized by their ability to bind to the receptor's active site or allosteric sites, thereby blocking its activation by natural ligands. The structure of EGFR-IN-5 likely includes specific functional groups that enhance its binding affinity and selectivity for the EGFR, contributing to its potential efficacy in treating various cancers, particularly those with EGFR mutations or overexpression. Additionally, the pharmacokinetic properties, such as solubility, stability, and bioavailability, are essential for its therapeutic application. As with many targeted therapies, understanding the compound's mechanism of action, potential side effects, and resistance mechanisms is crucial for its clinical use.

(1-(6-((5-(4-(Dimethylamino)Piperidin-1-Yl)Pyridin-2-Yl)Amino)-2-((4-Fluorophenyl)Amino)Pyrido[3,4-D]Pyrimidin-4-Yl)Piperidin-4-Yl)Methanol

<p>EGFR-IN-5 inhibits EGFR &amp; mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>

CAS 2225887-26-1

EGFR-IN-5

EGFR-IN-5

Ref: IN-DA01N3GD

EGFR-IN-5

Ref: 54-BUP01848

(1-(6-((5-(4-(Dimethylamino)Piperidin-1-Yl)Pyridin-2-Yl)Amino)-2-((4-Fluorophenyl)Amino)Pyrido[3,4-D]Pyrimidin-4-Yl)Piperidin-4-Yl)Methanol

Ref: 54-PC108742

EGFR-IN-5

Ref: TM-T11160